| Autor: |
Butler, J. Anker, S.D. Filippatos, G. Khan, M.S. Ferreira, J.P. Pocock, S.J. Giannetti, N. Januzzi, J.L. Piña, I.L. Lam, C.S.P. Ponikowski, P. Sattar, N. Verma, S. Brueckmann, M. Jamal, W. Vedin, O. Peil, B. Zeller, C. Zannad, F. Packer, M. the EMPEROR-Reduced Trial Committees Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Popis: |
Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. Methods and results Health status was assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence of baseline KCCQ-CSS (analyzed by tertiles) on the effect of empagliflozin on major outcomes was examined using Cox proportional hazards models. Responder analyses were performed to assess the odds of improvement and deterioration in KCCQ scores related to treatment with empagliflozin. Empagliflozin reduced the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS tertiles [hazard ratio (HR) 0.83 (0.68-1.02), HR 0.74 (0.58-0.94), and HR 0.61 (0.46-0.82) for |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
